Bile duct cancer, also known as cholangiocarcinoma, is a type of cancer that forms in the bile ducts. The symptoms of bile duct cancer may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever.
Increasing prevalence of bile duct cancer has driven the market growth, For instance, according to American Cancer Society report 2018, each year around 8,000 people in the U.S. are diagnosed with cholangiocarcinoma. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers.
Market Dynamics
Key players are focusing on product approvals to strengthen their position in the global bile duct cancer market. In February 2021, Eisai Co., Ltd., a pharmaceutical company, received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its Fibroblast Growth Factor (FGF) receptor selective tyrosine kinase inhibitor E7090.
Key features of the study:
- This report provides an in-depth analysis of the global bile duct cancer market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bile duct cancer market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market
Detailed Segmentation:
- Global Bile Duct Cancer market, By Treatment Type:
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Oxaliplatin
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- Global Bile Duct Cancer market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bile Duct Cancer market, By Region:
- North America
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Oxaliplatin
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Oxaliplatin
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Oxaliplatin
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Oxaliplatin
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Oxaliplatin
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Oxaliplatin
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Incyte Corporation*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eisai Co., Ltd.
- QED Therapeutics, Inc.
- Agios Pharmaceuticals, Inc.
- RenovoRx
- Ability Pharmaceuticals
- Imbrium Therapeutics L.P.
- Delcath Systems, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
